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Abstract: The Essure™ system for permanent contraception was developed as a less invasive 
method of female sterilization. Placement of the Essure™ coil involves a hysteroscopic transcer-
vical technique. This procedure can be done in a variety of settings and with a range of anesthetic 
options. More than eight years have passed since the US Food and Drug Administration approval 
of Essure™. Much research has been done to evaluate placement success, adverse outcomes, 
satisfaction, pain, and the contraceptive efficacy of the Essure™. The purpose of this review is 
to summarize the available literature regarding the efficacy, safety, and patient satisfaction with 
this new sterilization technique.
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Introduction
On the spectrum of women’s health issues, contraception is a leading topic of   discussion. 
According to data gathered by the National Surveys of Family Growth in 2006–2008, 
the Centers for Disease Control reports that more than 99% of sexually experienced 
women have used at least one contraceptive method.1 Of all the contraceptive options, 
tubal sterilization was utilized by 10.3 million women.1 Tubal sterilization was second 
only to oral contraceptive pills, which were used by 10.7 million women.1 The history 
of tubal sterilization has evolved dramatically since its introduction in the nineteenth 
century. Most recently, transcervical tubal sterilization techniques have offered women 
less invasive approaches for permanent contraception.
Developing reliable methods of hysteroscopic sterilization has proven an elusive 
goal. Since its first description in the mid 1800s, various substances have been used for 
tubal occlusion, including heat, mechanical plugs, and other chemical agents.1–3 In 2002, 
Essure™ (Conceptus Inc, San Carlos, CA) became the first permanent   contraceptive 
system to be approved by the US Food and Drug Administration (FDA).1,3 Since that 
time, there has been a growing body of literature describing its safety, efficacy, and 
acceptability.
Description
The Essure™ system is a minimally invasive alternative for permanent female 
sterilization.4–6 Essure™ utilizes a transcervical hysteroscopic approach to place 
permanent microinserts into the fallopian tube ostia bilaterally. The microinserts com-
prise an inner coil composed of stainless steel/polyethylene terephthalate fibers and 
an outer coil of nitinol, a nickel-titanium alloy.3 The nitinol coil deploys and expands Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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to anchor into the proximal fallopian tube.3 The inner coil is 
composed of polyethylene terephthalate fibers which induce 
local tissue ingrowth and fibrosis, resulting in eventual 
occlusion of the fallopian tube.3,7 This is a benign tissue 
response that takes several weeks for the desired result of 
complete tubal lumen occlusion to occur.6 Therefore, a 
confirmatory test is required three months after Essure™ 
placement to confirm bilateral tubal occlusion. In the US, 
this test is a hysterosalpingogram.6 Until this imaging study 
has been completed, patients must be properly educated on 
the need for another form of reliable contraception, such as 
oral contraceptive pills, Depo-Provera®, transdermal or trans-
vaginal contraceptive patches or rings, barrier methods, or 
abstinence. Absolute contraindications to use of the Essure™ 
include allergies to nickel, titanium, or contrast dye.2
Efficacy
The indicator of efficacy of the Essure™ device is the ability 
to prevent conception from occurring. The US Collaborative 
Review of Sterilization investigated the efficacy of 
various tubal sterilization techniques in 1996, prior to the 
development of the Essure™. These procedures included 
clip sterilization, unipolar coagulation, bipolar coagulation, 
and postpartum partial salpingectomy. Cumulative 10-year 
probability of pregnancy was determined to be about 18.5 
per 1000 female sterilization procedures.8,9 The failure rate 
range was 7.5–36.5 per 1000. This included tubal sterilization 
methods, such as postpartum partial salpingectomy, 
laparoscopic unipolar coagulation, Falope rings, interval 
partial salpingectomy, bipolar coagulation, and spring clips.8,9 
The manufacturer of Essure™ reports effectiveness rates of 
99.95%, 99.90%, 99.84%, 99.80%, and 99.74% at years 1, 
2, 3, 4, and 5, respectively.10
Success of the Essure™ is largely dependent on correct 
placement. Manufacturer data using the Essure™ system 
model ESS205 reports the bilateral placement rate to be 
94.6% after the first placement attempt.11 Various studies have 
reported initial placement success at a rate of 84%–98%.2 
The results of a prospective Phase III clinical trial funded 
by Conceptus Inc were reported in July 2003. This study 
demonstrated that bilateral placement of the Essure™ device 
was achieved in 90% (464) of the 518 women participating 
in their study.4 In these 464 women, bilateral placement was 
successful with only one procedure in 96%.4 The remaining 
18 women required a second placement procedure that was 
ultimately successful. Other studies, between the years 2004 
and 2010, have reported rates of initial Essure™ insertion 
ranging between 88% and 98%.7,12–16 These cases include both 
office and operating room settings, although some studies 
did not specify this.
When the initial attempt at Essure™ placement was not 
successful, the majority of patients were offered a second 
placement procedure. Many of these have been successful, 
raising the overall success rate for bilateral Essure™ placement 
to 92%–96%.4,16 Panel and Grosdemouge reported success 
with the Essure™ among 96.7% of the 492 patients included 
in their prospective multicenter study in 2006.14 Success was 
defined as bilateral placement of the Essure™ (on the first or 
second attempt) or unilateral placement with a history of a 
unilateral salpingectomy or confirmation of occlusion of the 
second fallopian tube via hysterosalpingogram.
Factors impeding bilateral placement from being possible 
include uterine anomalies and proximal tubal occlusion, 
tortuosity, spasm, or stenosis.3,4,15 In the Cooper et al study of 
518 patients, placement of the Essure™ was not attempted in 
2% because of uterine, cervical, or fallopian tube pathology 
preventing exposure of the tubal ostia.4 Anatomic factors, 
such as lateral tubes, endometrial polyps, uterine adhesions, 
stenotic tubes, obesity, and no visible tubal ostium, accounted 
for 77% of cases of failed bilateral placement in this 
2003 study.
Hysteroscopy revealed 0.6% of patients with intrauterine 
pathology in another study, preventing physicians from 
proceeding with Essure™ placement.14 In an office-based 
hysteroscopy analysis by Levie et al, 3% of patients were 
unable to have the Essure™ placed due to uterine pathology 
found at the time of hysteroscopy.12 Some of these clinical 
situations included cervical stenosis, laterally-placed 
fallopian tubes, bicornuate uterus, and endometrial polyps 
or endometrium blocking view of the ostia.
The use of nonsteroidal inflammatory agents prior to 
the procedure appeared to increase the success of Essure™ 
placement.3,13 In one study, women received an anti-
inflammatory agent 30–60 minutes before the procedure, 
along with a paracervical block. The patients also received 
intravenous sedation if needed. Anti-inflammatory agents 
have been suggested to work by decreasing tubal spasm 
during the procedure.17 However, this finding has not been 
replicated in all studies.14
Clinicians may encounter situations in which a patient 
has had a previous unilateral salpingectomy. A few studies 
have included these patients in their analyses, and shown 
successful placement and confirmation of tubal occlusion on 
hysterosalpingogram.14 This suggests that a previous unilateral Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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salpingectomy is not a contraindication to an Essure™ 
procedure for occlusion of the remaining fallopian tube. 
Some research has included women with a previous history 
of a salpingectomy and previous hysterosalpingographic 
documentation of unilateral tubal occlusion. Documentation 
of unilateral salpingectomy and subsequent postprocedure 
tubal occlusion are important parts of the counseling in 
these cases.
Since the development of the Essure™ system, Conceptus 
Inc has attempted to address these issues by continually 
updating and improving the coil catheter delivery system. 
The new coil catheter system was designed to carry the 
Essure™ coil past areas of higher tubal resistance. Kerin 
et al investigated this new version of the Essure™ in 2004 
and demonstrated a higher initial bilateral placement rate of 
98%.15 Such improvements in the device have been attributed 
to higher success with the initial procedure compared with 
the Phase II and Phase III trial data reported by Cooper et al4 
and Kerin et al in 200324.
Appropriate follow-up is necessary to determine 
the efficacy of this product. Patients must understand 
the importance of confirming tubal blockage and proper 
device placement with a subsequent imaging study. 
Without this objective evidence of tubal occlusion and/
or device placement, they cannot rely on the Essure™ for 
contraception.10 Until this confirmatory test, another reliable 
form of contraception must be used. The type of imaging 
study used for the Essure™ confirmation test varies according 
to location. The hysterosalpingogram is the method utilized in 
the US, but other countries rely on plain x-ray or transvaginal 
ultrasound to document placement.18,19
As  discussed,  three  months  following  initial 
placement of the Essure™ coils, patients must undergo a 
hysterosalpingogram to confirm bilateral tubal occlusion. 
Unfortunately, not all studies included this aspect in their 
analysis of success of the Essure™ procedure.7,12,14 Of the 
patients with successful bilateral placement of the Essure™, 
tubal occlusion rates are high, in the 92%–96% range.4,17,20 
Loss of patients at the three-month follow-up interval was 
a limitation in these studies. Compliance with follow-up 
has been documented to be as low as 12.7%.7,21 This 
differs drastically from the 98% compliance with a three-
month hysterosalpingogram reported elsewhere.4 Savage 
et al reported that 13% of their study population was lost 
to follow-up prior to obtaining a hysterosalpingogram.20 
Factors accounting for these differences may include patient 
education, cultural and economic barriers, and physician 
compliance. Lack of a follow-up hysterosalpingogram was 
the singlemost important factor contributing to pregnancies 
reported to the manufacturer worldwide between 1997 and 
2005.3,5,6
Physician experience does not appear to have a significant 
impact on efficacy. The Phase III clinical trial by Cooper et al 
included 20 physicians having a wide range of experience with 
hysteroscopy and the Essure™. Seventy percent of the physicians 
had no previous experience with the Essure™ system. Despite 
this, the physicians still had a high (.95%) success in placement 
with one procedure.4 Length of time for the procedure improved 
with experience, and bilateral placement rates did not change 
significantly.4 A larger retrospective study involving 884 women 
and 118 physicians at 30 different facilities had primary 
successful placement in 96.2% of these patients.20
Over the past few years, various patient characteristics 
have been investigated to determine if they have any effect 
on efficacy of the Essure™. Nulliparity, obesity, body mass 
index, previous abdominal surgery, and age have been 
evaluated in many studies, and have not been demonstrated 
to have an effect on success.4,13,14,20 One study did show 
higher successful placement in an outpatient versus inpatient 
setting, despite similar patient characteristics.20 Various 
uterine anatomy anomalies and pathology have been known 
to prevent placement of the Essure™ device.
Efficacy of the Essure™ device is ultimately determined 
by its contraceptive efficacy. Effectiveness in previous clinical 
trials has been defined as “a lack of pregnancies in women 
who have achieved bilateral placement, and have had a 
confirmatory hysterosalpingogram showing proper micro-coil 
location and occluded tubes”.17 Based on this criterion, there 
have been no reported pregnancies in the clinical trials.17 This 
includes data from a prospective, international, multicenter 
Phase II trial that reported no pregnancies after 9620 woman-
months of exposure to intercourse.4 In a retrospective review of 
tubal occlusion and risk factors for failure conducted at Kaiser 
Permanente in Northern California, three of 884 women who 
underwent hysteroscopic Essure™ sterilization conceived 
after the hysterosalpingogram was interpreted as bilateral 
tubal occlusion. However, subsequent internal review of 
these three cases determined that the Essure™ devices were 
not properly placed.20 Placement of the device during the 
follicular phase of the menstrual cycle is recommended 
by the device manufacturer. The two main reasons for 
this recommendation are ease of device placement with a 
thinner endometrial lining and to exclude the possibility of 
an early luteal phase pregnancy.11 The only four pregnancies 
encountered in the pivotal trial were in women who were 
pregnant at the time of Essure™ placement.11Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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In 2007, Levy et al reviewed the reported pregnancies 
after Essure™ sterilization to date.5 Of the estimated 50,000 
Essure™ procedures performed worldwide between 1997 
and 2005, there were 64 unintended pregnancies reported 
to the manufacturer. The causes of the pregnancies were 
evaluated by the reporting physician and manufacturer 
staff. Patient or physician noncompliance accounted 
for 47% of cases, followed by misinterpreted x-ray or 
hysterosalpingogram (28%), and then pregnancy at time 
of Essure™ placement (12.5%). One pregnancy was the 
result of Essure™ placement using a previous device design 
that is not available anymore. The other seven cases did 
not have sufficient information available to determine the 
cause or area of miscommunication. Examples of patient 
compliance issues included failure to return for three-month 
hysterosalpingogram and failure to use alternative methods 
of contraception before the hysterosalpingogram or after 
hysterosalpingogram confirmed tubal patency.5 These are 
areas in which patient education and follow-up reminders 
may substantially reduce the failure rate. Also, pregnancy 
tests within 24 hours of Essure™ placement and placement 
during the follicular phase of a woman’s menstrual cycle 
may avoid situations in which a patient is already pregnant 
at the time of Essure™ placement.
Safety
The American College of Obstetricians and Gynecologists has 
summarized the safety of traditional, nonhysteroscopic female 
sterilization techniques. Death from tubal sterilization is rare, 
with mortality rates in the US reported as 1–4 deaths per 
100,000 procedures.22 Traditional nonhysteroscopic female 
sterilization techniques carry an overall complication rate 
of 0.9%–1.6%.22 The data regarding safety of the Essure™ 
device has been reassuring. The incidence of adverse events 
on the procedure day has been in the range of 0%–3.1%.4,7,23 
These have included vasovagal response, hypervolemia from 
uterine distention media, and severe emesis secondary to 
pain medication.4 There were no major adverse events in the 
Phase II and pivotal trial data between 1998 and 2001.6,24 
The investigators classified “major adverse events” as death, 
bowel injury, and major vascular injury. “Perforation” is a 
potential complication of Essure™ placement. This has been 
reported in 0%–2.8% of patients in the literature.6,23 As a 
hysteroscopic-dependent procedure, the basic inherent risks 
of hysteroscopy are risks of the procedure itself. Hysteroscopy 
has proven to be a safe and well tolerated procedure which 
can be performed in a variety of settings.25 The safety of the 
procedure has been further confirmed by its successful use 
in high risk patient populations such as those with severe 
cardiac disease.26
Various side effects of Essure™ placement are discussed 
on the manufacturer’s website. These include symptoms dur-
ing or immediately after placement, such as mild to moderate 
cramping, nausea or vomiting, dizziness or lightheadedness, 
and bleeding or spotting.10 Additional adverse events can be 
explored by review of the Manufacturer and User Facility 
Device Experience database. This database is organized 
through the US FDA. Its utility is to represent reports of 
adverse events pertaining to various medical devices. The 
link to this website is http://www.accessdata.fda.gov/scripts/
cdrh/cfdocs/cfmaude/search.cfm.
For some patients and physicians, another appealing 
aspect of the Essure™ procedure is the possibility of 
performing the procedure in the office, rather than in the 
operating room. To date, research has supported the safety 
and efficacy of performing Essure™ procedure in both 
settings.12–14,16,20 The procedure can also be performed with 
a variety of anesthetic agents. However, these options will 
vary at each institution, based on available resources and 
preference of the surgeon, anesthesiologist, and patient.
A prospective, multicenter study in France did not find 
any differences in success rates between centers, despite each 
center determining its own location (operating room versus 
hysteroscopy room) of Essure™ placement.14 This group did 
not find any differences in success when they compared the 
types of anesthesia used. Their patient population utilized 
a variety of anesthetic options, including general, regional, 
intravenous sedation, local, and no anesthesia.
Nichols et al designed a multicenter, prospective study to 
compare Essure™ sterilization in the operating room versus 
the office.13 The location of the procedure was determined 
on an individual basis by physician and patient preference. 
Of the 320 women enrolled in this study, 252 procedures 
were completed in the operating room versus 68 in the office. 
There was no difference between procedure time, bilateral 
placement rate, or complications between the two groups. 
However, the office population did have higher gravidity, 
more use of preprocedure nonsteroidal anti-inflammatory 
agents, and more use of oral contraceptives prior to Essure™ 
placement. A criticism of this study is the lack of randomiza-
tion, which more accurately reflects the probable scenario 
practitioners will encounter. Patient preference will be a 
contributing factor when determining the location of Essure™ 
placement. Anesthesia choices varied between the operating 
room and office groups. The operating room group most 
frequently utilized a combination of paracervical block and Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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intravenous sedation, compared with the office group in 
which a paracervical block and an oral sedative combination 
was most common.
A recent publication in 2010 described the results of a 
randomized, blinded clinical trial investigating the effects 
of paracervical block with lidocaine on procedure pain 
compared with a saline placebo. There was no difference in 
successful placement or complications in either group.27
Another prospective study investigating the placement 
of Essure™ in the office setting had promising results.16 
The average procedure time was 12.4 minutes, and 96% of 
patients had successful bilateral placement of the Essure™ 
coils. They also had a 98% tubal occlusion rate at the three-
month postprocedure hysterosalpingogram.
Overall, the safety profile of the Essure™ device appears 
to be excellent. There has been no difference in safety between 
operating room and office procedures. Ongoing research will 
need to continue to address the safety profile in the long-term, 
such as 10 and 20 years from insertion. Another question that 
may arise is that regarding tubal sterilization and its protective 
effects on ovarian cancer. Does the Essure™ female steriliza-
tion provide the same protective benefits in reducing ovarian 
cancer risk as traditional sterilization techniques?
Patient acceptability
Overall, studies have demonstrated high satisfaction with 
the Essure™. In a six-year review of the Essure™, the 
literature has reported satisfaction and comfort rated as good 
to excellent in 96%–99% of women at follow-up visits.3 
As part of their Phase III study investigating the Essure™ 
device, Cooper et al evaluated satisfaction in a cohort of 
464 women with successful bilateral Essure™ microinsert 
placement. Comfort was rated as good to excellent by 99% at 
all follow-up visits. Another favorable aspect of this study was 
a shorter total procedure time compared with laparoscopy. The 
average time from procedure room entry to discharge from the 
facility was 80 minutes. As discussed in the previous section, 
the Essure™ has the appeal to many women of being a safe 
office procedure, if the medical facility has the necessary 
resources. Hysteroscopy time has been reported to be less 
than 15 minutes, on average, in both operating room and 
office settings.4,13,14,16
A study by Duffy et al compared laparoscopic tubal 
ligation with Essure™ hysteroscopic sterilization.28 The 
results showed that 82% of Essure™ patients reported 
procedure tolerance as “excellent to good” compared with 
41% of patients who underwent laparoscopic tubal ligation. 
This study evaluated patient satisfaction after a 90-day 
interval as well. Of the Essure™ patients, 100% were satisfied 
with their recovery, compared with 80% of the laparoscopic 
tubal ligation patients.
A 2010 publication by Levie et al specifically addressed 
the question of patient satisfaction with office-based Essure™ 
sterilization.12 The majority of these patients (70%) rated 
procedure-associated pain as equal to or less than their 
typical menstrual pain. Their follow-up surveys were very 
positive in regard to patient satisfaction. Follow-up surveys 
were collected for 84% of the study patients. Of these, 92% 
preferred having the procedure done in the office, 98% 
would recommend the procedure to a friend, and 93% would 
undergo the procedure again if necessary. It is not surprising 
that higher satisfaction was significantly correlated with 
lower average pain scores.
Only a few studies have evaluated postoperative recovery 
and patient symptoms. In the prospective Phase III trial 
published in 2003, the majority of the participants (58%) 
reported an uneventful recovery period.4 Of the 228 women 
who reported symptoms, the three most common ones 
were cramping (30%), pain (13%), and nausea (9%). These 
resolved in 56% of the women before discharge.
When addressing patient acceptability one must also 
consider cost. Essure™ has been shown to be a more cost 
effective option when compared to traditional laparoscopic 
sterilization.29 This is true even if both procedures are per-
formed in the operating room.30 
We do not yet have data describing the outcomes of 
Essure™ placement in women with a history of chronic pelvic 
pain, severe dysmenorrhea, or severe dyspareunia. Therefore, 
we do not have the ability to counsel these patients adequately 
on postoperative satisfaction. Whether the Essure™ device 
will have any effect on their symptomatology is unknown.
There is limited literature investigating patient accept-
ability of the Essure™ hysteroscopic sterilization option. 
Patient preference for tubal sterilization options has not been 
investigated since the addition of the latest hysteroscopic 
sterilization techniques. Understanding potential barriers, 
patient awareness, and misconceptions about tubal 
sterilization options would improve women’s health and 
physicians’ ability to educate patients on permanent female 
sterilization. As with all sterilization procedures, the patient 
should understand the permanent nature of the procedure. 
The patient should have no desire for future pregnancies.
Conclusion
When structured protocols are followed, Essure™ hystero-
scopic sterilization is an effective, safe, and well accepted Patient Preference and Adherence
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method of permanent sterilization. This review serves the 
purpose of providing information for practitioners to utilize 
when counseling their patients regarding the Essure™ 
permanent contraception option.
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